Bonn : The logistics company DHL Group closed the second quarter of 2025 with earnings growth, despite a volatile global environment. Revenue decreased by 3.9 percent compared to the previous year to EUR 19.8 billion, primarily due to the impact of exchange rate effects and slower momentum in trade volumes, while profitability improved. Operating profit was up 5.7 percent to EUR 1.4 billion, supported by cost improvements and yield management. The EBIT margin improved by 0.7 percentage points to 7.2 percent.

In the second quarter of 2025, DHL Group's gross capital expenditure (capex owned assets) amounted to EUR 608 million, 4 percent below previous year's levels. DHL Group continues to maintain tight capex control and is adjusting investments to the current economic environment. At the same time, the Group is investing organically and inorganically in growth markets and productivity improvements as part of its Strategy 2030. In the second quarter, DHL Group announced several investment programs, acquisitions, and partnerships, including investments in the Middle East of more than EUR 500 million between 2024 and 2030, with a focus on the rapidly growing Gulf markets of Saudi Arabia and the United Arab Emirates.

The Group is also expanding its capabilities in pharma logistics: In the second quarter, DHL Group completed the acquisition of CRYOPDP, a provider of courier services for clinical trials, biopharma, and cell and gene therapies. DHL Supply Chain will take advantage of the expertise of the newly acquired specialist provider and the global air freight services of DHL Express and DHL Global Forwarding to expand its pharma-specialized network and maximize its potential. Additionally, the expansion of the DHL Health Logistics Campus in Florstadt (near Frankfurt) will create the central DHL pharma hub in Europe.

With the acquisition of IDS Fulfillment in the USA and the strategic partnership with Evri in the UK, DHL Group is further expanding its capabilities in the structurally growing e-commerce business.